VBI Vaccines Inc (NASDAQ: VBIV) Adds Linda Bain To Its Board Of Directors: Sema4 Inducts Jason Ryan To Its Director Board

VBI Vaccines Inc (NASDAQ: VBIV) recruited Linda Bain to its director board. Linda will play an essential role with her extensive experience in promoting growth because VBI plans to accomplish corporate milestones. 

Linda will bring a wealth of experience in financial strategy and promote the growth of biotech companies’ businesses. CEO of VBI, Jeff Baxter, said the company is thrilled to welcome Linda to its director board. 

He further said Linda has an accomplished record of transforming scientific achievements into financial and organizational growth. In addition, Linda’s deep knowledge in the financial management/ life sciences industry makes her a pivotal director to transform VBI to achieve its corporate milestones.

Introduces 3-antigen hepatitis B vaccine 

Linda commenting on her appointment at VBI said she is thrilled to be part of VBI at a critical juncture. VBI has a dynamic management team and robust pipeline.  She plans to be part of the team of directors in helping the company chalking out a strategy in advancing several clinical candidates. In addition, VBI is preparing to unveil a 3-antigen hepatitis B vaccine candidate soon. 

Linda previously worked as a CFO at Codiak BioSciences, Inc, where she led it through its IPO and the follow-on financing. She also played a critical role in framing a strategic direction for Codiak and developed business and finance operations. 

Sema4 Recruits Jason Ryan To Its Director Board

Sema4 inducted Jason Ryan, a reputed executive, into its board of directors. Jason will commence working on the board of Sema4 after it combines its business with CM Life Sciences Inc (NASDAQ: CMLF). 

Jason recently worked as Chief Financing and Operating Officer of Magenta Therapeutics, which develops innovative medicines to treat patients with blood cancers and autoimmune diseases. 

Jason also led the early development of a molecular information company – Foundation Medicine, where he worked as a CFO. He also played a critical role in transforming Foundation Medicine into a global commercial organization. Roche Holdings finally took over Foundation Medicine. 

Sema4’s CEO, Eric Schadt, said Jason contributes an outstanding leadership role in the biotechnology and life sciences industries. Jason is also credited with scaling businesses and brings an impressive background in finance roles.

Leave a Comment

Your email address will not be published.